Clearside Biomedical Inc (CLSD) - Total Liabilities
Based on the latest financial reports, Clearside Biomedical Inc (CLSD) has total liabilities worth $65.59 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CLSD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Clearside Biomedical Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Clearside Biomedical Inc total assets.
Clearside Biomedical Inc Competitors by Total Liabilities
The table below lists competitors of Clearside Biomedical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Braille Energy Systems Inc
V:BES
|
Canada | CA$3.34 Million |
|
Candela Invest SA
BR:CAND
|
Belgium | €6.11 Million |
|
NewGenIvf Group Limited Class A Ordinary Shares
NASDAQ:NIVF
|
USA | $6.74 Million |
|
Star Pacific Tbk
JK:LPLI
|
Indonesia | Rp5.88 Billion |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
Australia | AU$6.83 Million |
|
M&C Saatchi
LSE:SAA
|
UK | GBX183.74 Million |
|
Miramar Resources Ltd
AU:M2R
|
Australia | AU$835.67K |
|
Edible Garden AG Inc
NASDAQ:EDBL
|
USA | $8.65 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Clearside Biomedical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Clearside Biomedical Inc (CLSD) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clearside Biomedical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clearside Biomedical Inc (2012–2024)
The table below shows the annual total liabilities of Clearside Biomedical Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $63.98 Million | +28.14% |
| 2023-12-31 | $49.93 Million | +22.69% |
| 2022-12-31 | $40.70 Million | +725.81% |
| 2021-12-31 | $4.93 Million | -53.33% |
| 2020-12-31 | $10.56 Million | -32.40% |
| 2019-12-31 | $15.62 Million | -23.81% |
| 2018-12-31 | $20.50 Million | +7.45% |
| 2017-12-31 | $19.08 Million | +45.04% |
| 2016-12-31 | $13.15 Million | -77.21% |
| 2015-12-31 | $57.71 Million | +95.56% |
| 2014-12-31 | $29.51 Million | +129.22% |
| 2013-12-31 | $12.88 Million | +1715.94% |
| 2012-12-31 | $709.00K | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more